Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes underwriting agrmnt
Inv. presentation
Asset disposition
Appointed CFO
Quarterly results
Director departure
Appointed director
|
|
ARCA biopharma, Inc. (ABIO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 04/24/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 02/24/2023 |
8-K
| Quarterly results |
| 02/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/03/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/28/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/20/2022 |
8-K
| Quarterly results |
| 08/02/2022 |
8-K
| Quarterly results|
Docs:
|
"Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, August 2, 2022 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are in the process of evaluating options for creating stockholder value, including potential development of our assets, partnering and other strategic options.” In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate s..." |
|
| 08/02/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/08/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/21/2022 |
SC 13D/A
| Funicular Fund, LP reports a 17.9% stake in ARCA biopharma, Inc. |
| 06/21/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
SC 13D/A
| Ma-Weaver Jacob reports a 17.9% stake in ARCA biopharma, Inc. |
| 05/11/2022 |
SC 13D/A
| Funicular Fund, LP reports a 16.6% stake in ARCA biopharma, Inc. |
| 05/05/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/18/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/14/2022 |
SC 13D/A
| Funicular Fund, LP reports a 15.1% stake in ARCA biopharma, Inc. |
| 04/04/2022 |
SC 13D/A
| Funicular Fund, LP reports a 13.5% stake in ARCA biopharma, Inc. |
| 03/28/2022 |
SC 13D
| Funicular Fund, LP reports a 6.5% stake in ARCA biopharma, Inc. |
| 03/18/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/14/2022 |
8-K
| Quarterly results |
| 03/14/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 01/27/2022 |
SC 13G
| BML Investment Partners, L.P. reports a 5.3% stake in ARCA Biopharma, INC. |
| 12/16/2021 |
8-K
| Quarterly results |
|
|
|